Ashvattha Therapeutics
PrivateLast Round
Series B
Extension
Jan 13, 2025
Total Funding Raised
$149.21M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Ashvattha Therapeutics is a biotechnology company that develops hydroxyl dendrimer therapeutics to address unmet medical needs in oncology, ophthalmology, and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ashvattha Therapeutics Comparables
Compare Ashvattha Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AsclepiX Therapeutics | 84% | |
| Aviceda Therapeutics | 81% | |
| Oculis Holding | 77% |
Ashvattha Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jan 13, 2025 | ||||
| Grant | Sep 1, 2022 | ||||
| Series B | Apr 27, 2022 | ||||
| Series A | Apr 29, 2021 | ||||
| Early Funding | Sep 1, 2020 | ||||
Seed | May 7, 2019 |
Ashvattha Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Natural Capital | Series B, Seed, Series B Extension |
| Plum Alley Investments | Series B |
| Tribe Capital | Series B, Seed, Series B Extension |
| Natural Capital | Series B Extension, Series B |
| National Institute on Aging | Grant |
| Sand Hill Angels | Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 46% MoM to 4.6K.
- Jan 9, 2026
George Montgomery appointed as new Executive Chairman.
Ashvattha Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Ashvattha Therapeutics's valuation, stock price, and market status.
Is Ashvattha Therapeutics a public or private company?
Ashvattha Therapeutics is a private company.
What is the current stock price of Ashvattha Therapeutics?
Ashvattha Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Ashvattha Therapeutics worth (valuation)?
Valuation information for Ashvattha Therapeutics is not publicly available.
Can I buy Ashvattha Therapeutics stock?
Ashvattha Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Ashvattha Therapeutics's last funding round?
Ashvattha Therapeutics's most recent funding round was Series B Extension on January 13, 2025.
Who are the main investors in Ashvattha Therapeutics?
Key investors in Ashvattha Therapeutics include Natural Capital, Tribe Capital.
Will Ashvattha Therapeutics IPO soon?
No public IPO plans have been announced for Ashvattha Therapeutics.
How can I track Ashvattha Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ashvattha Therapeutics's secondary market activity and sign up for updates.